# Study Evaluating Isovorin in Advanced/Recurrent Gastric Cancer

> **NCT00195572** · PHASE3 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 200 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Isovorin
- **DRUG:** TS-1

## Key facts

- **NCT ID:** NCT00195572
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-05
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2009-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00195572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00195572, "Study Evaluating Isovorin in Advanced/Recurrent Gastric Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00195572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*